Here are five things to know.
- While industry sources did not identify the entity interested in purchasing the business, they did estimate the deal could be worth as much as $2.5 billion, reported WSJ.
- The Canadian drugmaker acquired the eye-surgery business in 2013 through the acquisition of Bausch & Lomb.
- The eye unit sells lasers, tools and other equipment used in surgeries for glaucoma and cataracts, among other conditions.
- Valeant is also in talks with Japan-based Takeda Pharmaceuticals to sell its stomach drug unit, Salix Pharmaceuticals, for an estimated $10 million.
- The drugmaker is sitting on a $30 billion debt pile, which includes $12 billion in bank loans.
More articles on supply chain:
The election and slowing drug sales: 6 things to know about the rocky week for big pharma
Pfizer ditches cholesterol drug development over lack of commercial potential
Valeant eyes potential $10B deal with Takedo to sell stomach drug business
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.